Asia emerges new hotspot for healthcare ransomware, says report

Cyble’s 2026 healthcare threat report flags a sharp rise in Asia-focused ransomware, with hospitals, elderly care, and diagnostic systems increasingly in cybercriminal crosshairs

Solara Active Pharma dispatches final rights share call notice; Rs 112.5 per share due by May 7

API maker begins circulation of second and final call money notice for partly paid-up rights shares, completing the last leg of its 2024 fundraising cycle

WHO updates global guidelines to combat opioid crisis

Opioid dependence remains a major driver of death and disease worldwide

OneCyte and Kemp Proteins to revolutionize cell line development

Biopharma companies face persistent hurdles in cell line development, including long timelines, low yields, and high failure rates for novel molecules

Moderna to reveal late-breaking data on flu & RSV mRNA vax at ESCMID 2026

The data will be presented at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, April 17-21

KIMS Hospitals launches cutting-edge Neurosciences Institute in Mahadevapura

Neurocrine Biosciences to acquire Soleno Therapeutics for $2.9 billion

The acquisition adds VYKAT XR (diazoxide choline), the first FDA-approved therapy for hyperphagia in Prader-Willi syndrome (PWS), a rare genetic disorder, to Neurocrine’s portfolio

ImmunityBio responds to FDA concerns over promotional content

Biocon launches denosumab biosimilars Bosaya and Aukelso in US market

Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market

Lupin wins USFDA nod for generic Dapagliflozin tablets

Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market